Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cabometyx
Pharma
FDA cancels adcomm for Cabometyx in neuroendocrine tumors
Exelixis’ original announcement about a planned adcomm meeting came as somewhat of a surprise given positive findings from a phase 3 trial.
Angus Liu
Jan 10, 2025 9:46am
ICER calls out drugmakers over 'unsupported' price hikes
Dec 12, 2024 2:24pm
Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors
Nov 27, 2024 11:30am
Exelixis stock rises as Cabometyx withstands patent challenge
Oct 16, 2024 10:37am
Exelixis plots FDA prostate cancer filing despite survival miss
Sep 16, 2024 5:00pm
Exelixis joins Novartis on FDA waiting list in prostate cancer
Jan 25, 2024 8:00am
